This is a routine IP consolidation filing with no change in economics. The stock is unlikely to react materially. Monitor for IND filings for MIRA-55 and SKNY-1 as the next meaningful catalysts, as well as Phase 2a data for Ketamir-2.
Price Chart
Executive Summary
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to its MIRA-55 and SKNY-1 development programs. The agreement consolidates the company's intellectual property portfolio under a unified global rights structure but does not materially modify previously disclosed core economic terms. This is a routine IP consolidation filing with no new material financial data disclosed.
Key Financial Metrics
Key Facts
- MIRA entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC on June 3, 2026
- MIRA received worldwide exclusive rights to develop, manufacture, commercialize, and sublicense MIRA-55 and SKNY-1
- The amendment does not materially modify previously disclosed core economic terms
- MIRA-55 is an oral investigational drug candidate for chronic inflammatory pain; SKNY-1 is for obesity and addiction-related disorders
- Both candidates are preclinical-stage and have not been approved by the FDA
Financial Impact
No financial terms or economic consideration disclosed in the filing
Risk Factors
- Both MIRA-55 and SKNY-1 are preclinical investigational compounds with no FDA approval
- No new funding or partnership was announced alongside the license consolidation
- Company has a $42M market cap and is pre-revenue, making it sensitive to cash runway and dilution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027202 |
| Exhibit: ex99-1.htm | 0001493152-26-027202 |
| Document: 0001493152-26-027202-index-headers.html | 0001493152-26-027202 |
| Document: 0001493152-26-027202-index.html | 0001493152-26-027202 |
| Document: 0001493152-26-027202.txt | 0001493152-26-027202 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $0.6290 $0.6195 | ▼ −1.51% | ▼ −0.99% | $0.5500 (−12.56%) |
Oct 22, 2026 5d ago | Press Release | $0.6289 $0.6195 | ▼ −1.49% | ▼ −0.97% | $0.5500 (−12.55%) |
Sep 17, 2026 5w ago | 8-K | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5500 (−27.56%) |
Sep 17, 2026 5w ago | Press Release | $0.7593 $0.8323 | ▲ +9.61% | ▲ +9.73% | $0.5500 (−27.56%) |
Sep 1, 2026 8w ago | 8-K | $0.8600 $0.8495 | ▼ −1.22% | ▼ −1.66% | $0.5500 (−36.05%) |
Aug 6, 2026 11w ago | 8-K | $0.6782 $0.7400 | ▲ +9.11% | ▲ +8.50% | $0.5500 (−18.90%) |
Jul 10, 2026 15w ago | 8-K | $0.9245 $0.9097 | ▼ −1.60% | ▼ −0.84% | $0.5500 (−40.51%) |
Jul 6, 2026 16w ago | 8-K | $0.9549 $0.9478 | ▼ −0.74% | ▼ −0.27% | $0.5500 (−42.40%) |
Jun 17, 2026 18w ago | 8-K | $0.9782 $0.9524 | ▼ −2.64% | ▼ −3.42% | $0.5500 (−43.77%) |
Jun 8, 2026 20w ago | 8-K | $0.9767 $0.9802 | ▲ +0.36% | ▲ +1.93% | $0.5500 (−43.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers